David Calvet Canut on Takeda’s HyHub: A Shift Toward Patient-Centered Biologics
David Calvet Canut, Director TFE at UNIR, shared on LinkedIn:
“Takeda’s new HyHub™ system for HYQVIA® represents a significant advancement in patient-centered plasma-derived therapies. By simplifying subcutaneous immunoglobulin infusions, it enhances convenience and treatment adherence—areas where even small innovations can lead to meaningful improvements.
For biotech companies, this serves as a reminder that value creation now extends beyond just the molecule itself. Integration of devices, enhancement of patient experience, and home-based delivery are becoming crucial factors for competitive differentiation and securing reimbursement.
The field of plasma-derived therapies continues to evolve, and these hybrid therapy-plus-device models have the potential to redefine how we design, finance, and scale future biologics.”
Read full paper here.
Stay informed with Hemostasis Today.
-
May 14, 2026, 06:39Khushali Pandit: Innovations in Cell Therapy Manufacturing Highlighted at ISCT 2026
-
May 14, 2026, 06:09Sophia Delicou: A Shift Toward Function-Centered Care for Patients with Hemoglobinopathies
-
May 14, 2026, 06:04Tim Grisham: The Lasting Impact of Nurses in Hemophilia Care and Care Continuity
-
May 14, 2026, 05:19Tackling Cardiovascular Comorbidities in Bleeding Disorders – EHC
-
May 13, 2026, 17:38Rohit Sankar J. Snscphysio: Recognizing the Clot Before It Becomes Life-Threatening
-
May 13, 2026, 16:41Seema Dawood: When Elevated Platelets Signal a Myeloproliferative Neoplasm
-
May 13, 2026, 16:38Kari Tikkinen: Defining Thromboprophylaxis in MIBC Neoadjuvant Care
-
May 13, 2026, 16:28Nadia Tarhini: Evaluating the Risk of Recurrent Thrombosis in Children with ALL
-
May 13, 2026, 16:01Sifat Jubaira: When Low MCV Meets High Platelets